Immune Activation Could Hold the Key to Success of Dual-Target CAR T Therapy in Glioblastoma
Recurrent glioblastoma (GBM), a notoriously aggressive and lethal brain cancer, continues to pose a formidable challenge for oncology, partly due ...
Recurrent glioblastoma (GBM), a notoriously aggressive and lethal brain cancer, continues to pose a formidable challenge for oncology, partly due ...
In a remarkable advancement in the field of oncology, particularly in the treatment of hepatocellular carcinoma (HCC), recent research has ...
In the field of cancer immunotherapy, the NKG2D/NKG2DL axis represents a critical pathway that researchers are increasingly focused on targeting ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine